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ABSTRACT
OBJECTIVE: The objective of this study is to determine if Iron Sucrose (Venofer) is a safe
treatment for people with Chronic Kidney Disease.
STUDY DESIGN: This paper looks at three randomize controlled trials from 2001, 2007 and
2008.
DATA SOURCES: Randomized controlled trials that compared Iron Sucrose to Iron Dextran
and Iron Gluconate were found using OVID, Cochrane, Medline and Pubmed.
OUTCOME MEASURED: Adverse reactions that were analyzed based on serious and nonserious reactions to the iron preparations. Adverse reactions were also self reported or observed
by the same person for a minimum of one hour following infusion of iron therapy. Examples of
serious adverse reactions included anaphylaxis and death where as non serious adverse reactions
were reactions such as GI upset and headaches.
CONCLUSIONS: After reviewing all three RCT, Iron Sucrose (Venofer) is a safe iron
preparation for treating anemia associated with CKD.
KEY WORDS: CKD, Iron Sucrose, Venofer, parenteral iron, allergy, iron replacement, anemia
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Introduction
The diagnosis of Chronic Kidney disease has nearly doubled over the last ten years. Due
to the increase in end organ damage from high blood pressure and diabetes, to name a few, the
number of people diagnosed with CKD will continue to rise over the years to come.
One of the major co morbidities that is strongly associated with CKD is anemia. There
are many causes of the anemia associated with CKD; however some causes still remain
unknown. A few of the major causes of anemia associated with CKD are as follows: a
deficiency in EPO, frequent blood draws, GI hemorrhages, poor nutrition, coagulation of the
dialyzer for those on dialysis, and anticoagulation leading to a lack of iron storage. However, the
deficiency in erythropoietin of those with kidney disease remains the most significant cause of
anemia in those with renal insufficiency. Besides the deficiency in EPO, patients can already
have a deficiency in iron stores due to their low protein diet and a reduction in GI absorption due
to uremia. Therefore, the replacement of primarily EPO without sufficient iron replacement
therapy will not suffice in correcting the anemia in these patients.
Iron deficiency anemia is found in about 20-40% of patients on hemodialysis. The human
body contains about 2-4 g of iron. In a patient with chronic kidney disease, about 1-1.5 grams of
iron is lost during one year of dialysis. To correct this imbalance, it is necessary to use
supplements of iron, other than those of the oral route due to the lack of efficacy.
CKD is of relevance to physician assistants because 26 million Americans are affected
and millions of others are at an increased risk of developing renal insufficiency. Because obesity
is on the rise in America, co morbidities of obesity including hypertension and diabetes are also
on the rise putting more people at risk for developing CKD. CKD is associated with high rates
of morbidity and mortality, placing the patient in need of a good health care system.
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CKD can be associated with a major source to health care costs. It is estimated that 35
billion dollars is spent each year on patients with CKD. Many of the expenses related to CKD
are associated with hospital stays, dialysis costs, multiple medications and the treatments of
CKD co morbidities. In 2005, it was estimated that only 6.6 and 1.2% of Medicare patients were
CKD and end stage renal failure patients, but used 19.4 and 8.2 % of all Medicare funds. The
NHANES study showed that the number of physician visits greatly increased between early
stages of CKD with 4-5 visits and late stages of CKD and ESRD with 6-7 visits per year. It was
also estimated that patients with late stages of CKD had 2 hospitalizations per year with 14 visits
to the hospital.
CKD is a slowly progressing condition which is characterized by a decrease in the
function of the kidneys (decrease in the glomerular filtration rate) leading to volume overload,
hypertension, organ damage and uremia. The most common causes of CKD are hypertension and
uncontrolled diabetes. CKD is treated by a number of variables, all of which are important in
combination with each other in preventing the progression or slowing the progression of the
disease state. These methods include the use of ACE inhibitors for control of hypertension, but
also as kidney protection, diuretics, diet restriction, glucose control, parenteral iron replacement,
EPO, dialysis and transplant.
Parenteral iron replacement therapy is being recommended in the treatment of anemia
associated with CKD because oral iron supplementation has not shown to be effective. There are
a variety of parenteral iron replacements, some of which include Iron Sucrose and Iron Dextran.
Objective
The goal of this review is to determine if iron sucrose (Venofer) is a safe treatment for
people with chronic kidney disease.
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Methods
The studies chosen were all forms of randomized controlled trials. The first study was a
head to head, open label prospective RTC. The second; a prospective open label study and the
third a double blinded RTC. The inclusion criteria included people with CKD who were anemic
as a result of CKD, some also on hemodialysis. The subjects studied had either overt iron
deficiency anemia or were already being treated with a form of iron therapy to maintain Hgb
levels and prevent iron deficiency anemia. Iron sucrose (Venofer) was the intervention studied
in which its safety was compared to two alternative forms of parenteral iron which included Iron
Dextran and Iron Gluconate. The outcomes measured were several adverse reactions, looking at
the safety parameters of each type of iron therapy. Common adverse reactions measured
included: hypotension, pruritis, nausea, vomiting, fever, headache and urticaria.
After using Cochrane Database, I searched OVID, Medline and Pub med to find qualified
articles. Qualified articles were based on relativity to the topic chosen and were all patient
oriented evidence that matters or POEMs. Each article used was in English and all data used was
published between 2001 and 2008. In order to locate the RTC’s needed, key words searched
were ‘CKD’, ‘iron sucrose’, ‘Venofer’, ‘parenteral iron’, ‘allergy’, ‘iron replacement’ and
‘anemia’. Each article contained slightly different inclusion and exclusion criteria. However, all
subjects studied had CKD, some in different stages of kidney disease so that patients on
hemodialysis were included. Subjects excluded were those that did not have an anemia due to
iron deficiency, previous hypersensitivity to iron replacement therapy or some form of allergy
such as atopic allergy, asthma or eczema. Patients using a form of therapy to prevent allergic
reactions, such as anti-histamines, corticosteroids or immunosuppressive agents were also
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excluded from the study. Statistics included were P-values, Confidence Intervals, NNT, RRR,
and ARR.
Table 1. Demographics and Characteristics
Study

Type

# pt

Age

Tokgoz
2007
(1)

Randomized,
double
blinded,
controlled

60

21-80

Bahner
2001
(2)

Prospective,
open
randomized
controlled
trial

59

44-74

Hemodialysis
for 3 months,
rHuEpo
therapy for
min 4 mo,
hemoglobin
btw 9 and 12,
serum ferritin
btw 100 and
600 mcg/L,
normal serum
B12 and folic
acid conc.

Anirban
2008
(3)

Head to Head,
open label,
prospective
randomized
control trial

370

27-57

Adult CKD
patients who
were on
conservative
management
or on renal
replacement
therapy

Outcomes Measured

Inclusion
Criteria
Patients with
end stage renal
failure

Exclusion
Criteria
The Hgb levels
had to be
below 10g/dl,
transferrin sat
below 20%,
and serum
ferritin level
below
100mcg/L
No infection,
malignancy or
surgery;
No chronic
inflammatory
disease and no
blood
transfusions in
the last 3
months.

W/D

Interventions

0

75 mg of iron
sucrose or Iron
Dextran,
diluted in 100
ml saline
administered
over 30
minutes.

4

Iron overload,
hypersensitive
to iron
preparations,
NON- iron
deficiency
anemia, atopic
allergy, eczema
or asthma, liver
problems,
infections,
inflammatory
joint disease,
steroids, a goal
of >1L/h
volume
removal

31

Iron sucrose
was given to
27 pt (250 mg
diluted in
100ml of NSS,
infused over 60
minutes once a
month).
Iron Gluconate
was given to
28 pt (62.5 mg
over 5 min
1X/week at
dialysis)
Iron dextran100mg in
100ml NSS
over 30min,
Iron
Gluconate125mg diluted
in 100ml NSS
over 60. Iron
sucrose-100mg
diluted in
100ml of NSS
over 15 min.
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The outcomes of each study were the occurrences of adverse drug reactions. The adverse
drug reactions measured had slightly different ways of being monitored. Bahner et al measured
adverse reactions based on observation of the patients during the trial period and then self
reported adverse reactions by the patient. Patients also had the opportunity to fill out
questionnaires about the adverse reactions they were having. Anirban et al measured outcomes
based on timing of drug administration such as adverse reactions at time of test dose, time of
infusion and within the minutes after infusion and then again at 48 hours after. Sav et al
measured outcomes by having each subject observed by the same person for an hour after
infusion of iron therapy.
Results
In the study completed by Anirban et al, the efficacy of parenteral iron replacement is not
quantified. However, Anirban et al states that the efficacy of all offered iron therapies are
equivocal in nature, but the adverse event profile of each iron therapy is of concern. Sav et al
also refrains from discussing efficacy of iron replacement. In comparison, Kosch et al discusses
efficacy of two iron supplements, Iron Dextran and iron sucrose. The study concludes that from
baseline to 6 months of time, the efficacy of both parenteral supplements is equivocal and that
there is no statistically significant difference in the hemoglobin level, transferrin saturation and
ferritin levels. While there is not a significant difference in comparison between the two forms
of iron replacement, both iron sucrose and Iron Dextran had an increase in ferritin and transferrin
that was statistically significant with a p vale of less than 0.05. This was proven based on
comparison of baseline values and values after treatment at the 6 month mark. Moreover, it
appears that the decrease in hypochromic RBC is greater with the Iron Gluconate therapy,
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however, this is not the case due to the factor that the baseline for the hypochromic RBC group’s
baseline was much higher.
Table 2. Percent Mean Change comparing Iron Sucrose to Iron Gluconate
Iron Sucrose
(Baseline)
Hemoglobin
11.34
Ferritin
412
Hypochromic 6.3
RBC
Transferrin
21.9
Sat
White Cell
7.3
Count
Platelets
223.8
*= p value < 0.05

Iron
Sucrose
(After tx)
11.43
650*
4.6

%
mean
change
0.8%
58%
27%

Iron
Gluconate
(Baseline)
11.33
369
10.8

Iron
Gluconate
(After tx)
11.42
650*
5.2

% mean
change

33.3*

52%

25.7

34.4*

34%

7.7

5%

7.3

7.2

250.5

12%

227.6

230.3

Decrease
1%
1%

0.8%
76%
52%

Sav et al compared the safety of Iron Sucrose and Iron Dextran. The adverse reactions
anticipated were: hypo or hypertension, chest pain, skin reactions, nausea, vomiting, flushing,
myalgia, syncope, headache, fever, bronchospasm, paresthesias and dyspnea. These were
considered early reactions. Late adverse reactions examined were considered as adverse
reactions occurring within 48 hours of administration of the iron therapy. The p value was
greater than 0.05 meaning that there was no significant difference in the safety of either Iron
Sucrose or Iron Dextran. While no serious reactions occurred, the patients who were using Iron
Sucrose reported diarrhea as the only adverse reaction while those on Iron Dextran reported
having headaches. Using Iron Dextran as the control, for every 17 subjects, one subject would
have an adverse reaction calculated in table 3 as NNH.
Ganglui et al compared serious and non-serious adverse reactions of Iron Sucrose, Iron
Dextran and Iron Gluconate. Ganglui et al listed a number of serious adverse reactions; however
the common theme of all of the serious adverse reactions were those that need immediate
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attention and or resuscitation. Table 4 lists the serious adverse reactions. Of all three iron
therapies, Iron Dextran had the most serious side effects compared to the other two therapies.
The OR was 4.908, with a 95% CI and a p value of 0.018. The non serious adverse reactions
were not statistically significant with a 95% CI. Also, the number of people that discontinued
their therapy with Iron Dextran was statistically significant with a p value of 0.009 and 95% CI.
Those with serious adverse reactions had anaphylactic reactions, pruritis, and hypotension.
However, it should be noted that those with the serious reactions had also had previous
sensitivity to other iron preparations. Fewer patients experienced serious adverse reactions such
as pruritis and postural dizziness on Iron Gluconate, while non-serious reactions were mostly
intestinal discomforts. The only serious adverse reaction with Iron Sucrose was hypotension. As
with Iron Gluconate, the majority of non-serious adverse reactions were gastrointestinal related.
Because there were three iron preparations compared in this randomized control trial, two NNH
were calculated using Iron Dextran and Iron Gluconate as the control. NNH calculated were 8
and 4 respectfully.
Kosch et al found that many of the adverse effects that occurred were also common
symptoms of people diagnosed with chronic kidney disease. The most common side effects
were flu syndrome, infections, sinusitis and pneumonia in which the physician following the
subjects ruled that these were not reactions due to the iron replacement therapy. Although Kosch
et al could not relate adverse reactions to the iron preparations, more subjects dropped out of the
Iron Sucrose Group than the Iron Gluconate group. For every six patients participating in the
study, one person would have some sort of adverse event.

Table 3. Numbers Needed to Harm comparing Iron Gluconate, Iron Sucrose and Iron Dextran
Author
RRI
ARI
NNH
Kosch et al
0.37
0.17
6
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(Iron Sucrose vs.
Iron Gluconate)
Sav et al
0.16
0.06
17
(Iron Sucrose vs.
Iron Dextran)
Ganguli et al
-0.6
-0.12
8
(Iron Sucrose vs.
Iron Dextran)
Ganguli et al
-0.47
-0.07
14
(Iron Sucrose vs.
Iron Gluconate)
RRI-relative risk increase, ARI-absolute risk increase, NNH-numbers needed to harm
Table 4. Serious Adverse Reactions listed by Ganguli et al
Death
Bradycardia
Anaphylaxis
Arrhythmias
Cardiac Arrest
Coma
Myocardial Infarction
Seizures
Respiratory depression
Hypotension
Tachycardia
hypertension

Sepsis
Cyanosis

Discussion
Anemia is a common problem for people with CKD. However, it is known that oral
preparations of iron therapy are not as effective in people with chronic kidney disease.
Therefore, parenteral interventions of iron replacement therapy are necessary to correct anemia
in these people. Different forms of parenteral iron therapy have caused adverse reactions in the
past leading to the need to find an effective yet safe iron replacement therapy for these patients.
Over all, the articles that compared Iron Sucrose to Iron Dextran observed that Iron Sucrose has
led to less adverse reactions and seems to be safer without using a test dose on patients. It was
also noted that subjects who had previous reactions to Iron Dextran had no reaction to Iron
Sucrose.
Iron Sucrose labeled use is for people with chronic kidney disease who are affected by
anemia and those on dialysis with anemia. Off labeled uses include those with anemia who are
receiving chemotherapy. The latest data also shows the Iron Sucrose should be used in anyone
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who has had sensitivity to Iron Dextran. The majority of the articles share the limitation of small
sample size. Also, the open label study was a limitation to biases. Limitations that I ran across
were the inability to compare Iron Sucrose to a placebo or Iron Sucrose to each form of iron
preparations individually.
Conclusion
In comparison to Iron Dextran and Iron Gluconate, Iron Sucrose is a safe treatment for
anemia associated with Chronic Kidney Disease. In the article by Kosch et al, it is concluded
that although both Iron Sucrose and Iron Gluconate are effective and safe, there is a benefit to
Iron Sucrose because it is a once monthly dose where as Iron Gluconate is a once weekly dose.
Furthermore, Kosch et al note that this is an even greater benefit for those that are pre dialysis in
that there are fewer visits needed to be made to a clinic. Another benefit for those with CKD is
that previous sensitivities to Iron Dextran were not present when using Iron Sucrose. It was also
observed that even those patients that had adverse reactions of some sort may not be definitively
due to the iron preparation but based on numerous other health factors. It seems that the rate at
which the iron preparations are given can be a player in the number of adverse reactions that are
had and for those that are hypersensitive may benefit from a slower infusion rate.
Another area that is understudied is the effects of leukocytosis and its potential increased
risk for associated morbidities and infection. Although at this point, this reaction has only been
seen with Iron Gluconate, it is worth further investigation. As research in this area of medicine
expands, it may be helpful to research randomized dosages of the iron preparations so that there
aren’t as large of increases in hemoglobin, hematocrit and ferritin that is seen in some patients.
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